Fil d'Ariane

null Carlos Telleria, Ph. D.

Chercheur, IR-CUSM

Programme de recherche sur le cancer

Centre de médecine innovatrice

Professeur, Département de pathologie, Faculté de médecine, Université McGill

 

Mots-clés

ovarian cancer • drug repurposing • consolidation cancer therapy • peritoneal carcinomatosis • tumor dormancy

Publications choisies

Cliquez sur Pubmed pour voir la liste de mes publications

  • Goyeneche AA, Caron RW, Telleria CM. (2007). Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clinical Cancer Research 13: 3370-3379. PMID: 17545545.

  • Zhang L, Hapon MB, Goyeneche AA, Srinivasan R, Gamarra-Luques CD, Callegari EA, Drappeau DD, Terpstra EJ, Pan B, Knapp JR, Chien J, Wang XJ, Eyster KM, Telleria CM (2016). Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors. Molecular Oncology; 10: 1099-1117. PMID: 27233943.

  • Lisio M, Fu L, Goyeneche A, Gao Z, Telleria C (2019). High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. International Journal of Molecular Sciences 20, 952. PMID: 30813239.

  • Goyeneche AA, Lisio M-A, Fu L., Srinivasan R, Valdez J, Gao Z, Telleria CM (2020). The capacity of high-grade serous ovarian cancer cells to form multicellular structures spontaneously along disease progression is correlated with their orthotopic tumorigenicity in immunosuppressed mice. Cancers (Basel) 12, 699. PMID: 32188032.

  • Subeha M, Telleria CM (2020). The anti-cancer properties of the HIV protease inhibitor nelfinavir. Cancers (Basel) 12(11):E3437. PMID: 33228205.